Cargando…
60 mg·m(−2)·d(−1)柔红霉素联合标准剂量阿糖胞苷诱导治疗≤65岁初治急性髓系白血病患者的疗效和安全性分析
OBJECTIVE: To evaluate the long-term safety and efficacy of high-dose daunorubicin (DNR) (60 mg·m(−2)·d(−1)) combined with standard dose of cytarabine (DA) as induction therapy in patients under 65 years old with newly diagnosed acute myeloid leukemia (AML). METHODS: The complete remission (CR) rate...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364868/ https://www.ncbi.nlm.nih.gov/pubmed/27801323 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.10.015 |